Vaxcyte Inc. (PCVX)
Vaxcyte Inc. (PCVX) Stock Price, Analysis & Data
| Geld | n/a |
| Marktkapitalisierung | 8.9 Mrd |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -1.06 Mrd |
| Beta | 1.21 |
| EPS (ttm) | -7.58 |
| KGV (TTM) | n/a |
| Forward-KGV | -8.28 |
| KBV (TTM) | 3.14 |
| KUV (TTM) | n/a |
| Earnings Date | Nov 3, 2026 |
| Brief | n/a |
| Volumen | 555,623 |
| Ø Vol. (20D) | 1,410,637 |
| Eröffnung | 59.97 |
| Vortagesschluss | 60.22 |
| Tagesspanne | 59.50 - 60.86 |
| 52-Wk Range | 29.87 - 65.00 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über PCVX
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Vaxcyte 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -766.63 Mio, ein Anstieg von 65.25 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 2 Monaten · Simply Wall St.
Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial EnrollmentsVaxcyte recently completed enrollment for three Phase 3 adult clinical trials of its VAX-31 pneumococcal vaccine candidate, along with a Phase 2 VAX-31 infant study, and outlined plans to start a Phas...